Introduction
In recent years several new agents with single agent activity in non-small-cell lung cancer (NSCLC) have been identified [1] [2] [3] [4] [5] [6] . Single agent activity in NSCLC is generally defined as the ability to induce objective responses in at least 15% of patients. Among the new drugs are the taxanes, paclitaxel and docetaxel, the antimetabolite gemcitabine and the vinca alkaloid vinorelbine. When combined with cisplatin, several of these drugs have been demonstrated to result in higher response rates and increased median survival times compared with older combination regimens in patients with advanced stage NSCLC [2] [3] [4] [5] . Nevertheless, median survival times continue to be disappointing at approximately 10 months even when using the most active currently available regimens. Therefore, there is a continued need to identify new active drugs and combinations with novel mechanisms of action.
The camptothecins are a new class of drugs that act through inhibition of the enzyme, topoisomerase I, leading to cytotoxic DNA damage in the presence of ongoing DNA synthesis [7] [8] [9] . They include irinotecan (CPT-11), topotecan and 9-aminocamptothecin (9-AC). Irinotecan has been shown to have single agent activity in small-cell and NSCLC, and several other types of solid tumors [10] [11] [12] [13] . Japanese data using CPT-11 in NSCLC have been favorable; its evaluation in the USA is currently in progress. Topotecan has activity in smallcell lung cancer and ovarian cancer. Activity in NSCLC has been less promising and appears to be restricted to squamous cell histology [14] [15] [16] .
9-AC is a semisynthetic camptothecin derivative with broad preclinical activity against solid tumors including breast, colon cancer, and brain tumors [17] [18] [19] [20] . In two phase I studies its administration as a 72-hour continuous intravenous infusion repeated every two or three weeks was evaluated [21, 22] . Dahut et al. [21] reported the maximum tolerated dose (MTD) as 47 ug/m 2 /h without granulocyte-colony-stimulating factor (G-CSF) support with two of eight patients developing dose-limiting neutropenia. With G-CSF, escalation to 59 ug/m 2 /h resulted in dose-limiting neutropenia in six of 14 patients; five of these also developed grade 4 thrombocytopenia. Additional toxicities included fatigue, diarrhea and nausea/vomiting which affected 8% of patients as grade 3 toxicity. Neutropenia was suggested to correlate with steady state 9-AC lactone plasma concentrations. While initially 59 ug/m 2 /h x 72 (or 1416 ug/m 2 /day) repeated every other week was identified as the recommended phase II dose, a full evaluation of all data suggested that 47 ug/m 2 /h x 72 with G-CSF or 35 ug/m 2 /h x 72 without G-CSF support would be more appropriate [21] . Rubin et al. [22] also evaluated the 72-hour continuous dosing schedule, but administered the drug every three weeks. Their recommended phase II dose was 45 ug/m 2 /h every three weeks (without G-CSF). Leukopenia and thrombocytopenia were doselimiting. Based on these data, administration of 9-AC at 1416 ug/m 2 /day x 3 repeated every other week was chosen by the National Cancer Institute as dose and schedule for the phase II investigations. Phase II studies of this compound have been conducted [23] [24] [25] [26] .
Given the activity of irinotecan and topotecan in NSCLC, investigations of 9-AC in this disease appeared to be of high priority. The objectives of this phase II study were to evaluate 9-AC in the phase II setting in previously untreated patients with advanced NSCLC with an evaluation of response rates, toxicities, time to progression and survival times.
Patients and methods
Eligible patients had a histologic or cytologic diagnosis of stage 1MB NSCLC (cytologically positive pleural effusion or supraclavicular lymph nodes) or stage IV NSCLC. Patients had received no prior chemotherapy. Prior radiation was allowed as long as measurable disease was present in non-irradiated sites. Patients with brain metastases were eligible following palliative radiation therapy. All patients had a performance status of 0 to 2 (Cancer and Leukemia Group B) and clinically measurable disease, adequate bone marrow reserve with an absolute neutrophil count of at 1,500/mm 2 , platelet count 100,000/mm 2 and hemoglobin > 10 gm/dl, a serum bilirubin < 1.5 mg%, a creatinine =£1.5 mg%, and hepatic transaminases < 3 x normal. Patients were at least 18 years of age and signed an informed consent. There was no upper age limit.
Treatment plan
The initial treatment plan called for administration of 9-AC at 1416 ug/m 2 /d x 3 days (59 ug/m 2 /h x 72) by CVI through a central venous access device, every 14 days. G-CSF administration was initiated 24 hours after completion of 9-AC on day 5 at 5 ug/kg/day subcutaneously and continued until the post-nadir granulocyte count exceeded 10,000/mm 2 . Following observation of excessive toxicity in the first 13 patients the 9-AC dose was decreased to 1100 ug/m 2 /day x 3 by CVI followed by G-CSF administration as described above.
Dose modifications were performed according to previously observed toxicities. For grade 4 leukopenia. neutropenia. and thrombocytopenia exceeding four days duration or complicated by neutropenic fever, the 9-AC dose was reduced to 900 ug/m 2 /day x 3 days. For further such toxicity at 900 ug/m 2 /day. this dose was further reduced to 700 ug/m 2 /day. For grade 3 non-hematologic toxicity excluding alopecia and anemia, therapy was held until resolution of toxicity to grade < 2 and then resumed at 900 ug/m 2 /day. For grade 4 nonhematologic toxicity, therapy was held until the resolution of toxicity to grade < 2 and then resumed at 700 ug/m 2 /day. Subsequent cycles were administered when the total neutrophil count had recovered to > 1.500; mm" and a platelet count to > 100,000/mm 2 .
Statistical evaluation
This study was designed to enroll an initial group of 14 patients. If one response was seen in the first 14 patients, an additional 26 patients were to be enrolled to construct a 95% CI of 20% ± 12% for a targeted response rate of 20%. Disease status was assessed after every four cycles of therapy. All partial or complete responses required confirmation with a second evaluation at least four weeks following the first documentation of response. Responses were confirmed by a central audit and review panel. All patients were followed until death. A dose reduction was required after observation of excessive toxicity in the first 13 patients The two-stage study design was subsequently applied to a complete phase II patient cohort (45 patients) at the 1100 ug/m 2 / day dose.
Complete response (CR) was defined as disappearance of all known disease as determined by two observations not less than four weeks apart. A partial response (PR) was defined as a 50% decrease in size of measurable tumor lesions, measured by two observations not less than four weeks apart. In addition, there could be no appearance of new lesions or progression of any previously known lesions. Stable disease (SD) was defined as a decrease in total tumor size of less than 50% or increase of less than 25%. Progressive disease (PD) was defined as an increase in the size of a measurable lesions or the appearance of new lesions. Duration of partial response was measured from the first time that partial response was documented until the time of documented disease progression. Time to progression was measured from the time of first administration of 9-AC until documentation of progressive disease. Survival was measured from administration of the first dose of 9-AC until the date of death. Patients were treated for a maximum of eight cycles for stable disease. Administration of subsequent therapy was not specified. Therapy could continue for additional cycles in responding patients.
An exact CI for the combined response rate (CR and PR) was calculated using the binomial distribution. Kaplan-Meier estimates of the progression-free and overall survivor functions were computed and plotted, and 95% CI for the survivor function were obtained by the usual method of applying the Normal approximation to log(-log(S,) and then transforming back to obtain an interval for S,. Cox regression models were fit to both time until progression and survival time, including as covariates disease stage (IV vs IIIB), 9-AC dose (45 vs. 59 ug/m 2 ), performance status (0, 1, or 2), best response (PD vs. PR/SD), and whether second line chemotherapy was administered (yes or no). Age and gender were also included as covariates. The adequacy of the models was checked using plots of the log-cumulative hazard function. Plots of the score residuals were also examined for deviations from the model. All reported P-values are two-sided.
Drug formulation
9-AC was provided by the Clinical Trials Evaluation Program, Division of Cancer Treatment, National Cancer Institute. 9-AC was supplied in 5 mg/ml amber ampules diluted in 1 ml of dimethylacetamide (DMA). Each 5 mg ampule was supplied with a 49 ml amber vial of special diluent containing polyethylene glycol 400 (51%). with 0.01 M phosphoric acid buffer (49%). For preparation, using a glass syringe, 1 ml of the 9-AC concentrate was added to the special diluent vial. The final solution of 9-AC was filtered through a 5 micron filter. The resulting mixture contained 100 ug of 9-AC per ml in 2% dimethylacetamide. 50% polyethylene glycol 400, and 48% 0.01 M phosphoric acid. This 9-AC solution was further diluted in 0.9% sodium chloride injection, with a final concentration of less than 1 ug/ml. 9-AC was not diluted in 5% dextrose. 9-AC was administered by ambulatory infusion pump. The drug is not compatible with standard infusion fluids and therefore was not further diluted (except as noted in the previous paragraph). Administration was by continuous intravenous infusion.
The infusion was prepared on a daily basis

Results
This study opened in April of 1994 and closed to accrual in April of 1996. Follow-up is available through November of 1997. A total of 58 patients from five institutions were entered. The patient demographics are listed in Table 1 . Fifty-seven percent of patients were male, 50% had adenocarcinoma, and 83% had performance status 0 or 1. Seventy-one percent of patients had stage IV disease.
Response
The response information is summarized in Table 2 . Patients received between one and 12 cycles. The median number of cycles was four. Overall, 54 patients were evaluated for response. Four patients received only one cycle and were unevaluable for response (two patients requested to discontinue therapy, one required hospitalization for removal of an infected port, and one patient's insurance company refused support). A total of five patients had a partial response ranging from nine to 28 weeks in duration. Twenty-two patients had stable disease and 27 had progressive disease. The overall response rate for all 58 patients is 8.6% (95% CI: 2.9%-19%). Three of the responding patients had adenocarcinoma and two had undifferentiated NSCLC.
Survival
The median time to progression was 2.3 months for the entire study cohort. The progression-free survival at six months was 15.8% (7.8%-26.3%). The overall median survival was 5.4 months and one-year survival rate 30.4% (19%-42.5%). The one-year survival rate was 56.2% for 27 patients who received second line chemotherapy (35%-73%). Patients who received no further chemotherapy had a one-year survival rate of 9.7% (2.5%-22.9%). The progression-free and overall survival functions are displayed in Figures 1, 2 , and 3. Second line chemotherapy was administered to 27 patients and consisted of single-agent chemotherapy in five patients, a two-drug chemotherapy regimen in 14 patients, and a three-drug regimen in eight patients.
A Cox regression model fit to the time until progression showed that patients with a lower performance status were more likely to experience disease progression (e.g., HR = 2.1 for 2 vs. 0, P = 0.098). With respect to survival, patients with either a PR or SD had a considerably lower hazard of death than those with PD (HR = 0.2, P < 0.001). In addition, the hazard of death was lower for those given second line chemotherapy (HR = 0.2, P < 0.001) and for female patients (HR = 0.4, P = 0.02).
Toxicity
The toxicities are outlined in Tables 3 and 4 frequent grade 4 neutropenia (6 of 13 patients) and/or thrombocytopenia (5 of 13 patients). With subsequent dose reduction to 1100 ug/m 2 /d, only 14 of 45 patients experienced a grade 3 or 4 neutropenia and eight had grade 3 or 4 thrombocytopenia. Neutropenic fever was observed in one patient and three patients for the two dose levels, respectively. There were no toxic deaths. Other toxicities were mild to moderate in severity.
Discussion
In this phase II study of 9-AC in NSCLC we demonstrate a modest response rate of 9.3% in patients without 
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Survival time (months) Figure 3 . Survival according to administration of second line chemotherapy.
prior chemotherapy. Responses were observed at two dose levels and at the lower dose of 1100 ug/m 2 /day the drug was well tolerated. Thus, the study confirms the feasibility of a 72-hour schedule and acceptable toxicity at the lower dose of 1100 ug/m 2 /d with G-CSF support. However, the overall median survival time of 5.4 months is disappointing suggesting that patients benefited little, if any, from therapy with this drug at this dose and schedule.
Multiple studies in recent years have clarified the role of chemotherapy and NSCLC. It has been conclusively Table 3 . 9-AC NSCLC at 1416 ug/m 2 /day (59 ug/m 2 /day (« = 13) Worst grade toxicities (n = 13). demonstrated that chemotherapy prolongs survival when compared with best supportive care [27, 28] and that newer agents such as vinorelbine, paclitaxel, or gemcitabine, in combination with cisplatin or carboplatin appear to be more active than previously used combinations. Median survival times with these regimens range from 8-10 months. Given the survival time of 5.4 months in our study it may be questioned whether previously untreated NSCLC patients should be exposed to an experimental agent as first line therapy. In our study, patients received up to 12 cycles and continued treatment until disease progression was documented. Patients receiving a second line chemotherapy had a more favorable one-year survival rate of 47%. It is unclear, however, what criteria were applied in selecting patients for a second line chemotherapy among the many participating institutions; nevertheless, it would appear wise to limit exposure to a new agent to a fixed number of cycles, at least in patients who fail to achieve partial or complete response.
Topoisomerase I inhibitors are thought to be highly schedule dependent in their activity. It is possible that the modest activity profile of 9-AC observed in this study could be increased by a more prolonged exposure to this agent [29] [30] [31] . A phase I study at the National Cancer Institute is currently investigating administration of the drug for five days for two out of three weeks, or three out of four weeks [31] . In these studies, a new colloidal dispersion (CD) formulation of the drug is being used. Investigations of this or similar schedules in patients with NSCLC appear to be worthwhile. It is also possible that administration of topoisomerase I inhibitors with cisplatin, other chemotherapy drugs, or radiation therapy might lead to a synergistic interaction. However, the pursuit of such studies should be postponed until the demonstration of a higher single-agent activity profile in advanced disease.
Given the continued lack of curative therapy for advanced NSCLC, studies of new agents remain a necessity. While this study did not succeed at identifying a sufficiently active single-agent dose and schedule of 9-AC, the observed response rate of 9% supports further investigations of additional schedules of this compound and is similar to that of other single agents, including cis-or carboplatin [1, 3] . In addition, clinical investigations of other new drugs with novel mechanisms of action need to be pursued. However, given the poor median survival time in this study and the availability of well tolerated, modestly active standard chemotherapy regimens we are planning to limit exposure of NSCLC patients that do not respond to an experimental agent to two cycles followed by planned additional standard combination chemotherapy.
